ADAR1 Capital Management, LLC bought 2,640 shares of InMed Pharmaceuticals Inc. at $13.10 for $34.6k on Nov 5, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
10% owner
10%
Filed Nov 9, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$34,571.59Shares × reported price
Shares traded
2,640Common Shares
Price per share
$13.10Reported price. Read footnotes for ranges.
% of reported position traded
2.76%This security and ownership context
Holdings after
98,297Indirect · See Footnote
Trade date
Nov 5, 2026Buy
Filed
Nov 9, 2026, 8:18 PM ET5-day reporting delay
Accession
0001940272-26-000031Code P · Transaction 396528
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 95,657 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

MTRI price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MTRI · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 17, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.9500 to $13.3000, inclusive. Each Reporting Person undertakes to provide to Mentari Therapeutics, Inc., any security holder of Mentari Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: On November 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its outstanding common stock. The transaction reported herein occurred on November 5, 2026, after giving effect to the reverse stock split. On November 6, 2026, the Issuer completed its previously announced merger transaction and changed its name from InMed Pharmaceuticals Inc. to Mentari Therapeutics, Inc. and its trading symbol from INM to MTRI. Following completion of the merger and related transactions, the Reporting Persons ceased to beneficially own more than 10% of the Issuer's outstanding common stock and are no longer subject to Section 16. F3: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. F4: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.